儿童非高危朗格汉斯细胞组织细胞增生症治疗实践指南  

Practice guideline for the treatment of non-high-risk Langerhans cell histiocytosis in children

作　　者：儿童重要血液性疾病精准诊疗体系的建立及应用项目组 王宏胜 富洋 翟晓文 Project Team for the Establishment and Application of the Precision Diagnosis and Therapeutics in Children′s Major Hematological Disorders;Zhai Xiaowen

机构地区：[1]不详 [2]国家儿童医学中心,复旦大学附属儿科医院血液科,上海201102

出　　处：《中华转移性肿瘤杂志》2024年第5期415-421,共7页Chinese Journal of Metastatic Cancer

基　　金：国家重点研发计划(2022YFC2705003)。

摘　　要：朗格汉斯细胞组织细胞增生症(LCH)是单核-巨噬细胞系统的罕见病,经过数十年临床试验方案的更迭,有效的化疗药物已普遍应用。随着基础研究的进展,该病的治疗逐渐引入新的方案及新型靶向药物,改善了部分患者的预后。由于该病有明显的临床异质性,不同累及范围和危险程度患者的治疗方案可有较大差异,为了有效、安全地治疗儿童LCH,根据证据级别和临床用药经验,项目组特别组织专家编写了儿童非高危LCH治疗实践指南,旨在为临床治疗提供参考,指导临床医护人员合理治疗儿童LCH。Langerhans cell histiocytosis(LCH)is a rare disease of the mononuclear phagocyte cell system.Over several decades of clinical trial iterations,effective chemotherapeutic agents have become widely used.With advancements in basic research,new treatment protocols and novel targeted therapies have been gradually introduced,the prognosis has been improved for some patients.Due to the significant clinical heterogeneity of this disease,treatment regimens can vary greatly depending on the extent and severity of involvement.To ensure the effective and safe treatment of LCH in children,experts have compiled a practice guideline on the management of non-high-risk LCH,based on levels of evidence and clinical experience.This guideline aims to provide a reference for clinical treatment and guide healthcare professionals in the rational management of LCH in children.

关 键 词：朗格汉斯细胞组织细胞增生症 非高危 儿童 治疗 指南 

分 类 号：R725.9[医药卫生—儿科]